News|Articles|November 20, 2026

Sac-TMT Meets OS End Point in Pretreated Gastroesophageal Adenocarcinoma

Fact checked by: Tim Cortese

Sacituzumab tirumotecan significantly improved overall survival in third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma.

The phase 3 TroFuse-015 trial (NCT06356311) met its primary end point of overall survival (OS) with sacituzumab tirumotecan vs treatment of physician's choice (TPC) in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who received 2 or more prior lines of systemic therapy, according to a news release from the developer, Merck.1 At final analysis, sacituzumab tirumotecan demonstrated a statistically significant and clinically meaningful improvement in OS vs TPC.

What did TroFuse-015 show beyond OS?

The OS results were generally consistent across subgroups regardless of TROP2 expression status. Sacituzumab tirumotecan did not meet the secondary end point of progression-free survival (PFS) by blinded independent central review (BICR). Objective response rate (ORR), also a secondary end point, nominally favored sacituzumab tirumotecan, but was not formally tested under the prespecified analysis plan. The safety profile was consistent with previous studies of the agent, and no new safety signals were observed. The release did not report hazard ratios or median OS values; the data will be presented at an upcoming medical meeting and shared with regulatory authorities.

“Sac-TMT is the first TROP2 [antibody-drug conjugate (ADC)] to improve OS in a global phase 3 study in advanced gastroesophageal adenocarcinoma compared to TPC, demonstrating its potential in a particularly challenging disease setting,” stated Marjorie Green, senior vice president and head of oncology, global clinical development, at Merck Research Laboratories.1 “There is a tremendous unmet need for therapies that can improve survival for these patients. We look forward to discussing these data with regulatory authorities and sharing with the scientific community on behalf of patients who may benefit.”

What was the design of TroFuse-015?

TroFuse-015 is a randomized, open-label, multicenter, global trial that enrolled 473 patients. Patients were randomly assigned to sacituzumab tirumotecan at 4 mg/kg on days 1, 15, and 29 of each 6-week cycle or to TPC, which consisted of 1 of 4 agents: trifluridine/tipiracil (Lonsurf) at 35 mg/m2 orally twice daily on days 1 to 5 and 8 to 12 of each 4-week cycle, irinotecan at 150 mg/m2 on days 1 and 15 of each 4-week cycle, paclitaxel at 80 mg/m2 on days 1, 8, and 15 of each 4-week cycle, or docetaxel at 75 mg/m2 on day 1 of each 3-week cycle.1

Eligible patients were 18 years or older with histologically or cytologically confirmed advanced unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma.2 Additional criteria included measurable disease per RECIST v1.1, disease progression after at least 2 prior lines of chemotherapy or immunotherapy regimens, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. TROP2 expression was not required for enrollment and was a stratification factor, along with geographic region and ECOG performance status.

The primary end point was OS. Secondary end points were PFS, ORR, and duration of response, each assessed by BICR per RECIST v1.1, as well as safety and tolerability.

What is sacituzumab tirumotecan and how does it fit into the TroFuse program?

Sacituzumab tirumotecan is an investigational TROP2-directed ADC with a belotecan-derived topoisomerase I inhibitor payload and a bifunctional linker designed to maximize payload delivery to tumor cells and limit payload loss in circulation. Kelun-Biotech developed the agent, and Merck holds exclusive rights to develop, manufacture, and commercialize it outside Greater China.

TroFuse-015 is the second positive phase 3 readout in the TroFuse program, which includes 18 ongoing global phase 3 trials across multiple tumor types.1 In TroFuse-005 (NCT06132958), another phase 3 trial in the program, sacituzumab tirumotecan improved OS vs TPC in pretreated endometrial cancer (median, 19.0 vs 12.1 months; HR, 0.68; 95% CI, 0.55-0.84; P = .0001).3 The FDA has accepted a biologics license application under priority review for the agent in that setting, with a target action date of June 15, 2027.4

References

  1. Merck announces TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT) met primary endpoint of overall survival (OS) in third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. News release. Merck. November 20, 2026. Accessed November 20, 2026. https://tinyurl.com/46z9rd6b
  2. A study to evaluate sacituzumab tirumotecan (MK-2870) in advanced/​metastatic gastroesophageal adenocarcinoma (MK-2870-015) (TroFuse-015). ClinicalTrials.gov. Updated October 22, 2026. Accessed November 20, 2026. https://tinyurl.com/yck6zkav
  3. Lorusso D, Martin-Babau J, Backes F, et al. Sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer: results from the phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study. Presented at: 2026 European Society for Medical Oncology Congress; October 23-27, 2026; Madrid, Spain. Abstract LBA11.
  4. Merck & Co, Inc, Rahway, NJ, USA announces third-quarter 2026 financial results; highlights multiple milestones advancing broad, diverse pipeline. News release. Merck & Co Inc. October 29, 2026. Accessed November 20, 2026. https://tinyurl.com/mtv8hbx5

Related to this article